Market Overview

Nomura Downgrades Pharmacyclics To Neutral


Analysts at Nomura downgraded Pharmacyclics Inc. (NASDAQ: PCYC) from Buy to Neutral.

The price target for Pharmacyclics has been raised from $196 to $261.25.

Pharmacyclics shares have climbed 93.26% over the past 52 weeks, while the S&P 500 index has gained 11.87% in the same period.

Pharmacyclics' shares climbed 10.30% to close at $254.22 yesterday.

Latest Ratings for PCYC

Mar 2015Leerink SwannDowngradesOutperformMarket Perform
Mar 2015NomuraDowngradesBuyNeutral
Mar 2015Wells FargoDowngradesOutperformMarket Perform

View More Analyst Ratings for PCYC
View the Latest Analyst Ratings


Related Articles (PCYC)

View Comments and Join the Discussion!

Posted-In: NomuraDowngrades Analyst Ratings

Latest Ratings

PCTYJMP SecuritiesMaintains220.0
KMBRBC CapitalMaintains147.0
AZEKRBC CapitalMaintains50.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at